Wetzel Investment Advisors’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Wetzel Investment Advisors’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,000	Closed	-$603	–	946
2024 Q2	$603	Sell	1,000 -2,000	-67%	-$1.25K	﹤0.01%	856
2024 Q1	$1.89K	Buy	3,000 +2,000	+200%	+$1.23K	﹤0.01%	861
2023 Q4	$1K	Buy	+1,000	New	+$602	﹤0.01%	980

Wetzel Investment Advisors's VBIV Position: Q3 2024 in Review

Wetzel Investment Advisors sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 1,000 shares — an estimated $603 sold.

Wetzel Investment Advisors first reported a position in VBIV in Q4 2023 and held it in 3 quarters. The position peaked at $1.89K in Q1 2024. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.

Wetzel Investment Advisors reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
Wetzel Investment Advisors sold 1,000 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $603.
Wetzel Investment Advisors first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2023 and held it in 3 quarters.
Wetzel Investment Advisors's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $1.89K in Q1 2024.
1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.

Based on Wetzel Investment Advisors's 13F filing for Q3 2024, filed 29 Oct 2024.